Edobaxan

Edobaxan is an oral anticoagulant from the group of oxazolidinones that is approved in the EU. It acts as a factor Xa inhibitor. Edoxaban has the molecular formula C24H30ClN7O4S and is present in the drug as edoxabantosilate monohydrate. This is a white to pale yellow powder which is hardly soluble in water.

As an inhibitor of factor Xa, Edoxaban has antithrombotic properties. Factor Xa, a serine protease, plays a central role in the blood coagulation cascade (AlHajri L et al. 2017). Its half-life is between 10 and 14 hours. By inhibiting factor Xa, Edoxaban prevents the formation of thrombi.

• Prevention of stroke in atrial fibrillation with further concomitant disease or risk
• Prevention of embolism in atrial fibrillation with further concomitant disease or risk
• deep vein thrombosis
• Treatment of pulmonary embolism
• Prevention of recurrent vascular occlusion of deep veins (deep vein thrombosis)
• Prevention of recurrent pulmonary embolism

Edoxaban must not be used during pregnancy or while breastfeeding.

The normal daily dose is 60 mg. It is halved to 30 mg if the body weight is less than 60 kilograms, if kidney function is impaired or if drugs are used that interfere with the excretion of Edoxaban from the body. Edoxaban is taken once a day independently of meals.

The most common possible adverse effects include bleeding in various organs (nosebleeds, gastrointestinal bleeding, bleeding in the mouth and throat, - bleeding in the urogenital tract, vaginal bleeding, bleeding at puncture sites); also: nausea, increase in liver values, urticaria, itching, abnormal liver function tests.

Hypersensitivity to the ingredients, active bleeding, liver diseases with a risk of bleeding, increased tendency to bleed, recently completed operations on the brain, spinal cord or eyes, esophageal varices; vascular malformations, untreated high blood pressure, etc. Children and adolescents < 18 years.

Lixiana®

1. AlHajri Let al (2017) The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery
   :A Systematic Review.J Cardiovasc Pharmacol Ther 22:230-238.
2. Bounameaux H et al (2014) Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs 274: 1209-1231
3. Hughes GJ et al (2014) Edoxaban: an investigational factor xa inhibitor 39: 686-715
4. Lip GY et al (2014) Edoxaban: a focused review of its clinical pharmacology. Eur Heart J 35: 1844-1855
5. Neumann HA (2014) The coagulation system. ABW-Wissenschaftsverlag GmbH Berlin p. 58.